Transport of circulating IGF-I and LR3IGF-I from blood to extracellular wound fluid sites in rats.

Bastian SE, Walton PE, Belford DA

The Journal of endocrinology1 Jan 2000Cited by 7 (Europe PMC)

PMID10607940DOI10.1677/joe.0.1640077PepBankPUB-10607940

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Pharmacokinetics
In rats, (125)I-LR(3)IGF-I was removed from the circulation more rapidly than (125)I-IGF-I.
In plain wordsIn rats, the IGF-I analogue left the blood faster than natural IGF-I.
Peptide
IGF-1 LR3
Outcome
IncreaseRemoval from the circulation
Study
ratn: not reported in source
rats with subcutaneous wound chambers
Comparator
(125)I-IGF-I
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
10x10(6) c.p.m. · intravenous · single bolusAs given in this study (rat).
Source sentences
Summary
(125)I-LR(3)IGF-I was removed from the circulation more rapidly than (125)I-IGF-I in both sham control and chamber implanted rats.
2 context sentences(design, population, supporting numbers)
Summary · context
Wound chambers were implanted subcutaneously in the backs of adult male rats and left in place for 14 days.
Summary · context
A single i.v. bolus of either (125)I-IGF-I or (125)I-LR(3)IGF-I (10x10(6) c.p.m.) was administered via a jugular catheter and wound fluid and plasma samples taken at sequential time points between 5 and 240 min.
Report a problemFND-1060794002
02AnimalAnimal study (in vivo)Pharmacokinetics
In rats with implanted wound chambers, the steady state volume of distribution of (125)I-LR(3)IGF-I increased significantly compared with sham rats.
In plain wordsIn rats with wound chambers, the IGF-I analogue spread into a larger volume than in sham rats.
Peptide
IGF-1 LR3
Outcome
IncreaseSteady state volume of distribution
Study
ratn: not reported in source
rats with subcutaneous wound chambers
Comparator
Sham control rats
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
10x10(6) c.p.m. · intravenous · single bolusAs given in this study (rat).
Source sentences
Summary
Although implantation of the chambers did not alter the pharmacokinetic parameters of (125)I-IGF-I, significant increases in the steady state volume of distribution, clearance rate and half-life were recorded for (125)I-LR(3)IGF-I.
2 context sentences(design, population, supporting numbers)
Summary · context
Wound chambers were implanted subcutaneously in the backs of adult male rats and left in place for 14 days.
Summary · context
A single i.v. bolus of either (125)I-IGF-I or (125)I-LR(3)IGF-I (10x10(6) c.p.m.) was administered via a jugular catheter and wound fluid and plasma samples taken at sequential time points between 5 and 240 min.
Report a problemFND-1060794003
03AnimalAnimal study (in vivo)Pharmacokinetics
In rats with implanted wound chambers, the clearance rate of (125)I-LR(3)IGF-I increased significantly compared with sham rats.
In plain wordsIn rats with wound chambers, the IGF-I analogue cleared faster than in sham rats.
Peptide
IGF-1 LR3
Outcome
IncreaseClearance rate
Study
ratn: not reported in source
rats with subcutaneous wound chambers
Comparator
Sham control rats
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
10x10(6) c.p.m. · intravenous · single bolusAs given in this study (rat).
Source sentences
Summary
Although implantation of the chambers did not alter the pharmacokinetic parameters of (125)I-IGF-I, significant increases in the steady state volume of distribution, clearance rate and half-life were recorded for (125)I-LR(3)IGF-I.
2 context sentences(design, population, supporting numbers)
Summary · context
Wound chambers were implanted subcutaneously in the backs of adult male rats and left in place for 14 days.
Summary · context
A single i.v. bolus of either (125)I-IGF-I or (125)I-LR(3)IGF-I (10x10(6) c.p.m.) was administered via a jugular catheter and wound fluid and plasma samples taken at sequential time points between 5 and 240 min.
Report a problemFND-1060794004
04AnimalAnimal study (in vivo)Pharmacokinetics
In rats with implanted wound chambers, the half-life of (125)I-LR(3)IGF-I increased significantly compared with sham rats.
In plain wordsIn rats with wound chambers, the IGF-I analogue had a longer half-life than in sham rats.
Peptide
IGF-1 LR3
Outcome
IncreaseHalf-life
Study
ratn: not reported in source
rats with subcutaneous wound chambers
Comparator
Sham control rats
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
10x10(6) c.p.m. · intravenous · single bolusAs given in this study (rat).
Source sentences
Summary
Although implantation of the chambers did not alter the pharmacokinetic parameters of (125)I-IGF-I, significant increases in the steady state volume of distribution, clearance rate and half-life were recorded for (125)I-LR(3)IGF-I.
2 context sentences(design, population, supporting numbers)
Summary · context
Wound chambers were implanted subcutaneously in the backs of adult male rats and left in place for 14 days.
Summary · context
A single i.v. bolus of either (125)I-IGF-I or (125)I-LR(3)IGF-I (10x10(6) c.p.m.) was administered via a jugular catheter and wound fluid and plasma samples taken at sequential time points between 5 and 240 min.
Report a problemFND-1060794005
05AnimalAnimal study (in vivo)Pharmacokinetics
In rats with wound chambers, significantly more intact (125)I-LR(3)IGF-I than (125)I-IGF-I was recovered in wound fluid at each time point.
In plain wordsIn rats with wound chambers, more of the intact IGF-I analogue than natural IGF-I reached the wound fluid.
Peptide
IGF-1 LR3
Outcome
IncreaseIntact peptide recovered in wound fluid
Study
ratn: not reported in source
rats with subcutaneous wound chambers
Comparator
(125)I-IGF-I
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
10x10(6) c.p.m. · intravenous · single bolusAs given in this study (rat).
Source sentences
Summary
In addition, significantly more intact (125)I-LR(3)IGF-I was recovered in wound fluid than (125)I-IGF-I at each time point, although only 0.08% of administered (125)I-LR(3)IGF-I was recovered per ml of wound fluid at 240 min.
2 context sentences(design, population, supporting numbers)
Summary · context
Wound chambers were implanted subcutaneously in the backs of adult male rats and left in place for 14 days.
Summary · context
A single i.v. bolus of either (125)I-IGF-I or (125)I-LR(3)IGF-I (10x10(6) c.p.m.) was administered via a jugular catheter and wound fluid and plasma samples taken at sequential time points between 5 and 240 min.
Report a problemFND-1060794006
06AnimalAnimal study (in vivo)Pharmacokinetics
In rats with wound chambers, only 0.08% of the administered (125)I-LR(3)IGF-I was recovered per ml of wound fluid at 240 min.
In plain wordsIn rats with wound chambers, only a very small share of the injected IGF-I analogue reached the wound fluid after 240 minutes.
Peptide
IGF-1 LR3
Outcome
Not applicableShare of dose recovered per ml of wound fluid at 240 min
Study
ratn: not reported in source
rats with subcutaneous wound chambers
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
10x10(6) c.p.m. · intravenous · single bolusAs given in this study (rat).
Measurements
Recovery per ml wound fluid at 240 min
0.08%
(125)I-LR(3)IGF-I
Source sentences
Summary
In addition, significantly more intact (125)I-LR(3)IGF-I was recovered in wound fluid than (125)I-IGF-I at each time point, although only 0.08% of administered (125)I-LR(3)IGF-I was recovered per ml of wound fluid at 240 min.
2 context sentences(design, population, supporting numbers)
Summary · context
Wound chambers were implanted subcutaneously in the backs of adult male rats and left in place for 14 days.
Summary · context
A single i.v. bolus of either (125)I-IGF-I or (125)I-LR(3)IGF-I (10x10(6) c.p.m.) was administered via a jugular catheter and wound fluid and plasma samples taken at sequential time points between 5 and 240 min.
Report a problemFND-1060794007
07AnimalAnimal study (in vivo)Pharmacokinetics
In rats, a greater proportion of (125)I-LR(3)IGF-I than of (125)I-IGF-I was associated with lower molecular weight IGFBPs or existed as free peptide in both wound fluid and plasma.
In plain wordsIn rats, a larger share of the IGF-I analogue than of natural IGF-I was bound to small binding proteins or free.
Peptide
IGF-1 LR3
Outcome
IncreaseAssociation with low molecular weight IGFBPs or free peptide
Study
ratn: not reported in source
rats with subcutaneous wound chambers
Comparator
(125)I-IGF-I
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
10x10(6) c.p.m. · intravenous · single bolusAs given in this study (rat).
Source sentences
Summary
A greater proportion of (125)I-LR(3)IGF-I was associated with the lower molecular weight IGFBPs or existed as free peptide in both wound fluid and plasma.
2 context sentences(design, population, supporting numbers)
Summary · context
Wound chambers were implanted subcutaneously in the backs of adult male rats and left in place for 14 days.
Summary · context
A single i.v. bolus of either (125)I-IGF-I or (125)I-LR(3)IGF-I (10x10(6) c.p.m.) was administered via a jugular catheter and wound fluid and plasma samples taken at sequential time points between 5 and 240 min.
Report a problemFND-1060794008
08LabIn vitro (cells)Mechanism
In a model endothelial cell barrier, IGFBPs decreased IGF-I flux but did not affect Long R3 IGF-I flux.
In plain wordsIn lab tests with an endothelial cell barrier, binding proteins slowed IGF-I passage but did not slow the IGF-I analogue.
Peptide
IGF-1 LR3
Outcome
No significant changeFlux across a model endothelial cell barrier
Study
n: not reported in source
model endothelial cell barrier
Comparator
IGF-I
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
Dose not stated
Source sentences
Summary
IGF-I flux across a model endothelial cell barrier is decreased in the presence of IGFBPs, whereas flux of Long R(3)IGF-I (LR(3)IGF-I, an IGF-I analogue with low affinity for IGFBPs) is unaffected.
Report a problemFND-1060794001

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.